Tuberculosis (TB) resurged in the late 1980s and now kills approximately 3 million people a year. The reemergence of tuberculosis as a public health threat has created a need to develop new anti-mycobacterial agents. The Mtb-DNA Gyrase is an attractive target for development of new drugs due to its indispensable role in catalyzing the negative supercoiling of DNA and is essential for efficient DNA replication, transcription and recombination. Fluoroquinolone families of inhibitors are developed against the Mtb-DNA gyrase which show the best inhibition with DNA gyrase in the past. Due to the development of Multi-drug resistant Mycobacterium tuberculosis strains, the drugs showed less efficiency on the targets, recently, a new flouroquinolone inhibitor was identified (Galtifloxacin), which shown best inhibition. In this study we carried out Homology model of 0 Mtb-DNA gyrase, secondary structure analysis and active site analysis. Docking studies were also carried out with the Galtifloxacin and Amifloxacin and are helpful for further studies on the development of novel drugs against Mtb-DNA gyrase.
Key words: Mycobacterium tuberculosis, DNA gyrase, Galtifloxacin, Amifloxacin, Homology modeling, docking.
Copyright © 2021 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0